Papaverine is named as an intervention in 3 current clinical trials in our Israel and China registers. 2 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is First Affiliated Hospital of Wannan Medical College (1). The most-studied condition is Septic Shock.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Use of Papaverine to Shorten the Second Stage/Duration of Labor in Pregnant Women After Cervical Ripening by Double-balloon Catheter
NCT07237880 · ClinicalTrials.gov ↗ · Labor, Induced
|
Not applicable | Recruiting | Hillel Yaffe Medical Center | Israel |
|
Intravenous Papaverine for Term Prelabor Rupture of Membranes
NCT07826533 · ClinicalTrials.gov ↗ · Premature Rupture of Fetal Membranes
|
Not applicable | Recruiting | Wolfson Medical Center | Israel |
|
Papaverine and Sublingual Microcirculation in Septic Shock
NCT07657741 · ClinicalTrials.gov ↗ · Septic Shock, Microcirculatory Dysfunction, Sublingual Microcirculation
|
Not applicable | Not yet open | First Affiliated Hospital of Wannan Medical College | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| First Affiliated Hospital of Wannan Medical College | 1 |
| Hillel Yaffe Medical Center | 1 |
| Wolfson Medical Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Israel | 2 | 2 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Israel and China registers name Papaverine as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
First Affiliated Hospital of Wannan Medical College (1), Hillel Yaffe Medical Center (1) and Wolfson Medical Center (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Papaverine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Papaverine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Papaverine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.